New pill could bring relief to millions with severe eczema
NCT ID NCT07370909
First seen Jan 31, 2026 · Last updated May 09, 2026 · Updated 22 times
Summary
This study tests an oral medication called LW402 in 480 adults with moderate-to-severe atopic dermatitis (eczema). Participants will receive either the drug or a placebo for 16 weeks. The goal is to see if LW402 can significantly improve skin symptoms like redness, itching, and rash.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, China
Contact
Conditions
Explore the condition pages connected to this study.